Nov 9 (Reuters) – The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and diabetes.
The US Food and Drug Administration said it is requiring GLP-1 drugs such as Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy to add information to the “warnings and precautions” section of labeling about the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
The condition is a common cause of sudden, painless vision loss.
(Reporting by Christy Santhosh and Sneha S K in Bengaluru; Editing by Shilpi Majumdar)
